Adult

Baloxavir

General Information

Cap-dependent endonuclease inhibitor

Restricted formulary antimicrobial: For details see OUH netFormulary

Age restriction: 12 years – 64 years

For all information regarding interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).

Standard dose

Standard dose

Patient body weight

Oral baloxavir marboxil dose

80kg or more

80mg po single dose

20kg upto 80kg

40mg po single dose

Renal and hepatic impairment

Renal impairment

  • No dose adjustment required.

Hepatic impairment

  • Mild or moderate hepatic impairment (Child-Pugh class A or B): No dose adjustment is required.
  • Severe hepatic impairment (Child-Pugh class C): Safety and efficacy have not been established in this patient group.

References

  1. UK Health Security Agency (2025. Updated 23/1/26). Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. [online] Available at: https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents/guidance-on-use-of-antiviral-agents-for-the-treatment-and-prophylaxis-of-seasonal-influenza. [Accessed 31 Jan 2026]
  2. BNF. (n.d.). Baloxavir marboxil. [online] Available at: https://bnf.nice.org.uk/drugs/baloxavir-marboxil/ [Accessed 31 Jan 2026].
  3. Roche Products Limited. Summary of Product Characteristics. Xofluza 40 mg film coated tablets [online]. Last revision of the text 29/12/25. Available at: https://www.medicines.org.uk/emc/product/14764/smpc#gref [Accessed 31 Jan 2026].

Editorial Information

Last reviewed: 02 Feb 2026

Next review date: 01 Feb 2029

Author(s): AMST.

Approved By: ASG